The traditional method to evaluate DIPL is visual confirmation of myeloid bodies in tissues by electron microscopy. Electron microscopy has limited utility to monitor DIPL in humans because of the invasive nature of acquiring patient tissue biopsy samples. A qualified biomarker of DIPL in the blood or urine is needed to provide a more routine, non-invasive, and cost effective means to monitor DIPL in the clinic.
- Anderson N, Borlak J (October 2006). "Drug-induced phospholipidosis". FEBS Letters. 580 (23): 5533–40. doi:10.1016/j.febslet.2006.08.061. PMID 16979167.
- Reasor MJ, Hastings KL, Ulrich RG (July 2006). "Drug-induced phospholipidosis: issues and future directions". Expert Opinion on Drug Safety. 5 (4): 567–83. doi:10.1517/147403184.108.40.2067. PMID 16774494.
- Nonoyama T, Fukuda R (2008). "Drug induced phospholipidosis pathological aspects and its prediction". J Toxicol Pathol. 21: 9–24. doi:10.1293/tox.21.9.
- Shayman JA, Abe A (March 2013). "Drug induced phospholipidosis: an acquired lysosomal storage disorder". Biochimica et Biophysica Acta. 1831 (3): 602–11. doi:10.1016/j.bbalip.2012.08.013. PMC 3528828. PMID 22960355.
- Tengstrand EA, Miwa GT, Hsieh FY (May 2010). "Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities". Expert Opinion on Drug Metabolism & Toxicology. 6 (5): 555–70. doi:10.1517/17425251003601961. PMID 20370598.
|This medical article is a stub. You can help Wikipedia by expanding it.|